Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is experiencing strong financial results and growth in the transplant testing industry, with expansions through partnerships and acquisitions. The company has set ambitious financial targets, recently announced a new COO/CFO, and has a strong balance sheet, though lower profit margins are projected for 2027. The company's future success will also rely on the success of their new diagnostic solutions and competition from potential competitors such as Natera.

Bears say

CareDx is likely to continue to face challenges in gaining adoption and revenue growth due to the slow adoption of new products by clinicians and healthcare administrators. Despite positive developments such as the MXD acquisition and favorable LCD update, CareDx's financial targets may still be overly ambitious and require continued reliance on inorganic growth and potential capital raises. Additionally, the company's testing services are under scrutiny and may face further restrictions, leading to potential revenue declines.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.